Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRIVIACT vs APTIOM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Brivaracetam is a synaptic vesicle glycoprotein 2A (SV2A) ligand with high affinity. The exact mechanism by which it exerts its antiepileptic effect is unknown, but binding to SV2A is thought to modulate neurotransmitter release.
Selective enhancement of slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting excitatory neurotransmitter release.
Adjunctive therapy in the treatment of partial-onset seizures in patients 1 month of age and older with epilepsy
Adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy
50 mg orally twice daily; may increase up to 100 mg twice daily based on response and tolerability.
Initial: 50 mg orally once daily; titrate at weekly intervals by 50 mg twice daily increments to maintenance dose of 200 mg twice daily (400 mg/day). Maximum: 400 mg twice daily (800 mg/day).
Terminal elimination half-life is approximately 9 hours (range 7–11 hours). This supports a twice-daily dosing regimen (e.g., 50 mg twice daily) with steady state achieved within approximately 2 days.
Terminal elimination half-life ranges from 20 to 48 hours (mean ~32 hours). Steady-state achieved within 5-7 days.
Primarily hydrolyzed by amidase to a carboxylic acid metabolite (approximately 95% of dose). Minor oxidation by CYP2C19 and CYP2C9.
Primarily glucuronidation via UGT2B7; also metabolized by CYP3A4, CYP2C19, and CYP1A2 to a lesser extent.
Approximately 95% of the dose is excreted in urine as metabolites or unchanged drug (<1% unchanged). About 0.8% is excreted in feces via biliary elimination.
Primarily eliminated by hepatic metabolism, with approximately 95% excreted as metabolites in urine and <2% as unchanged drug. Fecal excretion accounts for about 5%.
≤20% bound to plasma proteins, predominantly albumin.
Approximately 90% bound to human plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 0.5 L/kg (range 0.3–0.6 L/kg), indicating distribution into total body water and extensive tissue binding.
Volume of distribution is approximately 1.3 L/kg, suggesting extensive distribution into tissues.
Oral: Essentially complete absorption with absolute oral bioavailability >90% (for tablets and solution). IV: 100% bioavailability.
Oral bioavailability is approximately 60% (range 53-68%).
For GFR ≥50 m L/min: no adjustment. For GFR 30-49 m L/min: 50 mg twice daily. For GFR <30 m L/min: 25 mg twice daily. Hemodialysis: 25 mg once daily with supplemental dose (up to 50 mg) after dialysis.
Estimated creatinine clearance (Cr Cl) >50 m L/min: no adjustment. Cr Cl 30-50 m L/min: reduce maintenance dose by 50%; Cr Cl <30 m L/min and not on hemodialysis: not recommended. Hemodialysis: 50 mg once daily with supplement of 25 mg after dialysis.
Child-Pugh A: no adjustment. Child-Pugh B: 25 mg twice daily (reduce by 50%). Child-Pugh C: not recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce maintenance dose by 50%; initiate at 50 mg once daily, titrate slowly. Child-Pugh Class C: contraindicated.
For ≥1 month to <16 years: initial 1-2 mg/kg/day divided twice daily; titrate to 2-4 mg/kg/day; maximum 200 mg/day. Weight-based dosing: 5-10 kg: 5-10 mg twice daily; 10-20 kg: 10-20 mg twice daily; 20-40 kg: 20-40 mg twice daily; >40 kg: 50-100 mg twice daily.
Children (≥4 years): Initial 1.5 mg/kg/day orally divided twice daily; titrate weekly by increments of 1.5 mg/kg/day to a maintenance of 3-6 mg/kg/day twice daily. Maximum: 400 mg twice daily.
No specific dose adjustment; initiate at 50 mg twice daily with caution; consider renal function due to age-related decline.
No specific dose adjustment based on age alone. Dose selection should be cautious, reflecting higher frequency of decreased renal/hepatic function and concomitant disease or drug therapy. Consider creatinine clearance and titrate slowly.
None
None
Suicidal behavior and ideation,Neurologic adverse reactions (somnolence, dizziness, ataxia, gait disturbance),Behavioral and psychiatric reactions (including aggression, agitation, anger, anxiety, depression, irritability, psychosis),Hypersensitivity reactions (including angioedema),Withdrawal of antiepileptic drugs (increase seizure frequency),Potential for QT prolongation (though not observed in studies, caution with other QT-prolonging drugs)
Suicidal behavior and ideation,Angioedema,Anaphylaxis,Dermatological reactions including Stevens-Johnson syndrome,Decreased serum sodium,Dizziness and gait disturbance,Hepatic injury
Known hypersensitivity to brivaracetam or any component of the formulation
Known hypersensitivity to eslicarbazepine acetate or any oxcarbazepine derivative
No significant food interactions. Grapefruit juice does not affect brivaracetam exposure. Alcohol may potentiate CNS depression and should be avoided or limited. High-fat meals do not alter absorption significantly.
Take with or without food. No specific food interactions reported.
Based on animal studies and limited human data, brivaracetam (Briviact) is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. In the second and third trimesters, exposure may be associated with adverse neurodevelopmental outcomes. The risk is dose-dependent and may be potentiated by concomitant use of other antiepileptic drugs. Preclinical studies have shown increased fetal loss, growth retardation, and skeletal abnormalities at clinically relevant doses.
Pregnancy Category D. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of fetal antiepileptic drug syndrome (facial dysmorphism, growth retardation, neurodevelopmental delay). Neonatal hemorrhage due to vitamin K deficiency may occur.
Brivaracetam is excreted into human breast milk. The milk-to-plasma (M/P) ratio has been reported as approximately 0.6-1.0 based on limited data. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Caution is advised due to potential for CNS adverse effects in breastfed infants. Monitor infant for sedation, poor feeding, and developmental milestones. The American Academy of Pediatrics considers brivaracetam compatible with breastfeeding, but individual risk-benefit assessment is recommended.
Excreted in human milk. Milk-to-plasma ratio not established. Potential for serious adverse reactions in nursing infants (sedation, poor suckling). Use only if benefit outweighs risk; consider alternative anticonvulsants.
Pregnancy may reduce brivaracetam serum concentrations due to increased clearance, primarily in the second and third trimesters. Therapeutic drug monitoring is recommended to guide dose adjustments. Dose increases of 20-50% may be necessary to maintain efficacy, especially during the third trimester. After delivery, doses should be gradually reduced to pre-pregnancy levels over 1-2 weeks, with close monitoring for seizure control. Initiate supplementation with folic acid (5 mg daily) before and during pregnancy to reduce neural tube defect risk.
Pregnancy increases clearance of eslicarbazepine acetate by approximately 30-40% in the second and third trimesters. Dose may require up to 50-100% increase from baseline to maintain therapeutic levels. Postpartum clearance returns rapidly; reduce dose promptly to avoid toxicity.
Brivaracetam is a high-affinity SV2A ligand similar to levetiracetam but with higher lipophilicity and brain penetration. Titration is not required; start at therapeutic dose. Monitor for psychiatric symptoms (irritability, aggression, depression) and somnolence. No need for therapeutic drug monitoring as efficacy correlates poorly with serum levels. Renal dose adjustment required for Cr Cl <30 m L/min. Bioavailability is nearly 100% with oral administration; IV formulation available for short-term substitution. Avoid abrupt discontinuation (seizure exacerbation possible).
APTIOM (eslicarbazepine acetate) is a once-daily antiepileptic drug for partial-onset seizures. Monitor serum sodium, especially in elderly or those on concomitant hyponatremia-inducing drugs. Titrate to maintenance dose over 2 weeks. Avoid abrupt discontinuation. Contraindicated in second- or third-degree AV block.
Take exactly as prescribed; do not stop suddenly without talking to your doctor, as seizures may worsen.,May cause dizziness, drowsiness, or problems with coordination. Do not drive or operate heavy machinery until you know how the drug affects you.,Notify your doctor if you experience mood changes, depression, aggression, or thoughts of self-harm.,Briviact can be taken with or without food. If you miss a dose, take it as soon as you remember, unless it is close to your next dose; then skip the missed dose.,Inform your healthcare provider of all medications you take, especially alcohol, other seizure drugs, or blood thinners.,Women of childbearing potential: discuss birth control options, as brivaracetam may reduce effectiveness of hormonal contraceptives (though less than some other anticonvulsants).,Store at room temperature, away from moisture and heat.
Take exactly as prescribed once daily; do not crush or chew tablets.,Report symptoms of hyponatremia: nausea, headache, confusion, lethargy.,Do not stop abruptly; withdrawal may increase seizure frequency.,Avoid driving until effects on dizziness or somnolence are known.,Notify doctor if pregnant, planning pregnancy, or breastfeeding.,Use effective contraception as APTIOM may reduce hormonal contraceptive efficacy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRIVIACT vs APTIOM, answered by our medical review team.
BRIVIACT is a Anticonvulsant that works by Brivaracetam is a synaptic vesicle glycoprotein 2A (SV2A) ligand with high affinity. The exact mechanism by which it exerts its antiepileptic effect is unknown, but binding to SV2A is thought to modulate neurotransmitter release.. APTIOM is a Anticonvulsant that works by Selective enhancement of slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting excitatory neurotransmitter release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRIVIACT and APTIOM depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRIVIACT is: 50 mg orally twice daily; may increase up to 100 mg twice daily based on response and tolerability.. The standard adult dose of APTIOM is: Initial: 50 mg orally once daily; titrate at weekly intervals by 50 mg twice daily increments to maintenance dose of 200 mg twice daily (400 mg/day). Maximum: 400 mg twice daily (800 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRIVIACT and APTIOM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRIVIACT is classified as Category C. Based on animal studies and limited human data, brivaracetam (Briviact) is associated with an increased risk of major congenital malformations, particularly neural tube defects, wh. APTIOM is classified as Category C. Pregnancy Category D. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.